EVGN earnings

Conference call and webcast: today, May 20, 2026, 9:00 AM ETREHOVOT, Israel, May 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the first quarter ended March 31, 2026.  Mr. Ofer Haviv, President & CEO of Evogene, stated: "Following the strategic transformation initiated in 2025, we are now focused on execution and advancing our tech engine for small-molecule dis

Zoom conference call scheduled for May 20, 2026, 9:00 AM ETREHOVOT, Israel, May 7, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the first quarter 2026, on Wednesday, May 20, 2026. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).To attend the conference, please register in advance:https://www.veidan-conferencing.com/evogeneThe entire conference will be available online on the

Conference call and webcast: today, March 05, 2026, 9:00 AM ETREHOVOT, Israel, March 5, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the fourth quarter and full year ended December 31, 2025.    Mr. Ofer Haviv, President & CEO of Evogene, stated: "During 2025, we executed a clear and decisive strategic shift. After a comprehensive review of our technology assets, target markets, and capital allocation priorities, we sharpened our focus to drive sustainable long-term value by co

Zoom conference call scheduled for March 5, 2026, 9:00 AM ET REHOVOT, Israel, Feb. 19, 2026 /PRNewswire/ -- Evogene Ltd . (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the fourth quarter and full year 2025, on Thursday, March 5, 2026. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).To attend the conference, please register in advance: https://www.veidan-conferencing.com/evogene The entire conference will be

Zoom conference call scheduled for November 20, 2025, 9:00 AM ET REHOVOT, Israel, Nov. 6, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the third quarter of 2025, on Thursday, November 20, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To attend the conf

Conference call and webcast: today, August 19, 2025, 9:00 am ET Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a subsidiary of Evogene and the MicroBoost AI for Ag operations, are presented as a single-line item in Evogene's consolidated statements of profit and loss for the first half of 2025. Their results are included under the line titled - "Loss from operations held for sale, net". This accounting treatment follows the intention to sell the majority of Lavie Bio's activities and the MicroBoost AI for Ag as of June 30, 2025.In the first half of 2025, total revenues amounted to approximately $3.2 million, compared to $2.3 million in the first half of

Zoom conference call scheduled for August 19, 2025, 9:00 AM ET REHOVOT, Israel, July 29, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Tuesday, August 19, 2025.   Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To attend the conference, please register in advance: https://www.veidan-conferencing.com/evogene The entire conference will be available online on the company's website a few day

Conference call and webcast: today, May 21, 2025, 9:00 am ET Financial Highlights: In the first quarter of 2025, total revenues were approximately $2.4 million, compared to approximately $4.2 million in the first quarter of 2024. The first quarter of 2024 revenues included license fee payments totaling $3.5 million - $2.5 million from Lavie Bio's license fee under its collaboration with Corteva, and $1.0 million from AgPlenus' license fee under its collaboration with Bayer. The primary driver of revenue in the first quarter of 2025 was an increase in seed sales by Casterra.During the fourth quarter of 2024 and the beginning of 2025, Evogene established an expense reduction plan which is expe

Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel, May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://www.veidan-conferenceing.com/evogene The entire conference will be available online on the company's website a fe

Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to approximately $5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.In Q4 2024, total revenues reached approximately $1.6 million compared to approximately $0.6 million in Q4 2023. The increase in revenues is mainly due to the increase in Casterra's seed sales.Revenues in Q4 2024 were originally expected to be higher, however, there was a change in delivery schedule of Casterra's seeds from 2024 to 2025. In

Zoom conference call scheduled for March 6, 2025, 9:00 AM ET REHOVOT, Israel, Feb. 20, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the fourth quarter of 2024, on Thursday, March 6, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://us06web.zoom.us/webinar/register/WN_1cToyoipTfW8X0xtgEqPfw The entire conference will be available online on the company's

Conference call and webcast: today, November 21, 2024, 9:00 am ET Financial Highlights: In the first nine months of 2024, total revenues reached approximately $6.9 million, compared to approximately $5.1 million in the first nine months of 2023.In Q3 2024, total revenues reached approximately $1.8 million, compared to approximately $3.8 million in Q3 2023. The revenues in Q3 2024 are mainly based on Casterra's seed sales. The revenues in Q3 2023 included a license fee payment of $2.5 million received by Lavie Bio.For the full year 2024, Evogene anticipates continued revenue growth, compared to the previous year, mainly due to Casterra's supply of existing seed orders.G&A expenses in Q3 2024

Zoom conference call scheduled for November 21, 2024, 9:00 AM ET REHOVOT, Israel, Nov. 7, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the third quarter of 2024, on Thursday, November 21, 2024. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance:https://us06web.zoom.us/webinar/register/WN_pG-Wc0JeQIifu1dmSUYOng The entire conference will be available online on the compa

Conference call and webcast: today, August 22, 2024, 9:00 am ET Financial and Business Highlights: H1 2024 revenues $5.1M, up from $1.3M in H1 2023; Q2 2024 revenues $914K, up from $654K in Q2 2023.Anticipated continued revenue growth in the second half of 2024 compared to the same period in the previous year, primarily driven by Casterra's initiation of supplying existing seed orders, which began in August 2024 and total over $8.0 million.H1 2024 loss $9.8M, down from $14.8M in H1 2023; Q2 2024 loss $6.0M, down from $7.8M in Q2 2023.Projected 2024 cash usage (excl. Biomica & Lavie Bio) $8.0M, down 36% from $12.5M in 2023.Implemented a 10:1 reverse stock split during July 2024.Casterra: Rece

Zoom conference call scheduled for 9:00 AM ET REHOVOT, Israel, Aug. 12, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the second quarter of 2024, on Thursday, August 22, 2024. Later that day, Company management, will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://us06web.zoom.us/webinar/register/WN_K5GBuG1FQ7Srbe_UJ7r2iQ The entire conference will be available online on the company's website a fe

Following the reverse share split, the Company will have approximately 5,079,000 Ordinary Shares issued andoutstanding REHOVOT, Israel, July 23, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) (the "Company" or "Evogene"), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, announced today that a reverse share split of its issued and outstanding Ordinary Shares, at a ratio of 1-for-10, is expected to be implemented after market close on July 24, 2024. The Company's Ordinary Shares will begin trading on the Nasdaq Capital

Conference call and webcast: today, May 23, 2024, 9:00 am ET Financial and Business Highlights: Q1 2024 revenue: $4.2M vs. $0.6M in Q1 2023; anticipating continued growth in 2024.Q1 2024 net loss: $3.8M vs. $7.0M in Q1 2023.Projected 2024 cash usage, excluding Lavie Bio and Biomica: $8.0M, down 36% from $12.5M in 2023.Ceasing Canonic's operations results in annualized savings of approximately $1.5 million.Casterra's new agreements with African and Brazilian castor seed growers secure 900 tons of castor seeds, expected to fulfill all standing orders by end of 2024.Biomica to present preliminary Phase 1 clinical trial results for BMC128 at the 2024 ASCO conference on June 3.Lavie Bio received

Zoom conference call scheduled for 9:00 AM ET REHOVOT, Israel, May 9, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2024, on Thursday, May 23, 2024. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://us06web.zoom.us/webinar/register/WN_GBxR-LTZRYy9D7OIt2YW0g The entire conference will be available online on the company's website a few days

Conference call scheduled for 9:00 AM ET REHOVOT, Israel, Feb. 26, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that it will release its financial results for the third quarter of 2023, on Thursday, March 7th, 2024.     Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference call, please use the following numbers: +1-888-407-2553 toll-free from the United States or +972-3- 9180608 internationally. Or at https://veid

Conference call and webcast: today, November 15, 2023, 9:00 am ET REHOVOT, Israel, Nov. 15, 2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based products utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the third quarter period ended September 30, 2023. Mr. Ofer Haviv, Evogene's President and Chief Executive Officer, stated: "The events in Israel since October 7, 2023, have brought about significant changes to our nation; we find ourselves at a time of profound reflection. Our hearts go out to all t

Conference call and webcast: today, August 17, 2023, 9:00 am ET REHOVOT, Israel, Aug. 17, 2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the second quarter period ended June 30, 2023. Ofer Haviv, Evogene's President and Chief Executive Officer, stated: "The second quarter of 2023 marked a period of remarkable achievements for the Evogene group. It was a pivotal point in the transformation that Evogene has been undergoing since the

Conference call scheduled for 9:00 AM ET REHOVOT, Israel, Aug. 1, 2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN)(TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that it will release its financial results for the second quarter of 2023, on Thursday, August 17, 2023. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference call, please use the following numbers: +1-888-281-1167 toll-free from the United States or +972-3-918-0609 internationally. You can also find access

Conference call and webcast: today, May 18, 2023, 9:00 am ET REHOVOT, Israel, May 18, 2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the first quarter period ending March 31, 2023. Mr. Ofer Haviv, Evogene's President and Chief Executive Officer, stated, "We have started 2023 strongly and are pleased with our business progress to date. We made significant improvements in recent months in the infrastructure and computational architec

Conference call scheduled for 9AM ET REHOVOT, Israel, May 4, 2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development, announced today that it will release its financial results for the first quarter of 2023, on Thursday, May 18, 2023. Later that day, Company management will host a conference call to discuss the results at 9:00AM Eastern time, 4:00PM Israel time. To access the conference call, please dial +1-888-281-1167 toll free from the United States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene

Conference call and webcast: today, March 9, 2023, 9:00 am ET REHOVOT, Israel, March 9, 2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, today announced its financial results for the fourth quarter and full year period ending December 31, 2022. Mr. Ofer Haviv, Evogene's President and Chief Executive Officer, stated, "We are very proud of the achievements made by Evogene and its subsidiaries in the past year. Throughout 2022, we made progress and have advanced the artific

Conference call scheduled for 9am ET REHOVOT, Israel, Feb. 27, 2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development announced today that it will release its financial results for the fourth quarter and full year 2022 on Thursday, March 9, 2023.  Later that day, Company management will host a conference call to discuss the results at 9:00AM Eastern time, 4:00 PM Israel time. To access the conference call, please dial +1-888-281-1167 toll free from the United States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website

Conference call and webcast: today, November 17, 2022, 9:00 am ET REHOVOT, Israel, Nov. 17, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, announced today its financial results for the third quarter, ended September 30, 2022. Mr. Ofer Haviv, Evogene's President and Chief Executive Officer, stated, "Reviewing our developments in 2022, the activities of Evogene and our subsidiaries are advancing well, and we have met important milestones. Each one, whose technology lever

Conference call scheduled for 9am ET REHOVOT, Israel, Nov. 7, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development announced today that it will release its financial results for the third quarter of 2022 on Thursday, November 17, 2022.   Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern time, 4:00 PM Israel time. To access the conference call, please dial +1-888-281-1167 toll free from the United States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website at www

Conference call and webcast: today, August 31, 2022, 9:00 am ET REHOVOT, Israel, Aug. 31, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for the second quarter ended June 30, 2022. Mr. Ofer Haviv, Evogene's President and Chief Executive Officer, stated, "We are very pleased with the two recent important developments that have taken place at the Evogene group: namely, the strategic collaboration and $10 million investment by ICL, a leading global specialty minerals company, into our subsidiary, L

REHOVOT, Israel, Aug. 2, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that it will release its financial results for the second quarter of 2022 on Wednesday, August 31, 2022.   On the day of the announcement, Company management will host a conference call to discuss the results at 9:00 AM Eastern time, 4:00 PM Israel time. To access the conference call, please dial +1-888-281-1167 toll free from the United States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's web

Conference call and webcast: today, May 26, 2022, 9:00 am ET REHOVOT, Israel, May 26, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for the first quarter ended March 31, 2022. Mr. Ofer Haviv, Evogene's President and Chief Executive Officer, stated, "Our subsidiaries continue to advance and we see many of them now at an inflection point, meeting critical milestones and the inherent value of our subsidiaries is becoming increasingly obvious. "Evogene's overarching goal is to revolutionize the dev

REHOVOT, Israel, May 10, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the first quarter of 2022 on Thursday, May 26, 2022. Dr. Elran Haber, Chief Executive Officer of Evogene's subsidiary, Biomica Ltd., will be joining the conference call to discuss Biomica's recent activity. On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial +1-888-281-1167 to

REHOVOT, Israel, March 10, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for the fourth quarter and full year of 2021, ended December 31, 2021. Mr. Ofer Haviv, Evogene's President and Chief Executive Officer, stated, "With 2022 well on its way and our subsidiaries successfully advancing on their developmental activities, we believe that we are progressing to significant value enhancing milestones. Moreover, we are very proud that our subsidiaries, Lavie Bio and Canonic, recently began commercia

REHOVOT, Israel, Feb. 15, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the full year and fourth quarter of 2021 on Thursday, March 10, 2022.     Financial Results and Earnings Announcement On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial +1-888-281-1167 toll free from the United States, or +972-3-918-0609 internationally. Access to the call

REHOVOT, Israel, Nov. 17, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for the first nine months and the third quarter of 2021, ended September 30, 2021. Mr. Ofer Haviv, Evogene's President and Chief Executive Officer, stated, "I am very pleased with the overall progress and achievement of milestones we see across the board in our subsidiaries and in Evogene itself. Our subsidiaries are progressing according to plan, and we expect to hit additional milestones in the coming months. With this ra

REHOVOT, Israel, Oct. 27, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the third quarter of 2021 on Wednesday, November 17th, 2021. Dr. Arnon Heyman, CEO of Canonic Ltd., Evogene's subsidiary, will be joining the conference call. On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial +1-888-281-1167 toll free from the United States, or +972-3-918-0

REHOVOT, Israel, Aug. 11, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across several market segments, announced today its financial results for the first half and the second quarter of 2021, ended June 30, 2021. Mr. Ofer Haviv, Evogene's President and Chief Executive Officer, stated, "As Evogene's subsidiaries continue to advance and mature, we feel that now is the time to introduce our strategy of how we will bring increased shareholder value in the near term from our subsidiaries. Our starting point is that each of our subsidiaries contains substantial intern

REHOVOT, Israel, July 28, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the second quarter of 2021 on Wednesday, August 11th, 2021. Ms. Sarit Firon Evogene's incoming Chairperson of the Board, will join the conference call to discuss her vision for Evogene. On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial +1-888-281-1167 toll free from the U